Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Clinical / R&D

Set Alert for Clinical R&D

Latest From Research & Development

UK-US Trans-Atlantic Precision Collaborations Target Pancreatic Cancer

A goal of "Precision Panc" in the UK and US-based "Precision Promise" is to create a knowledge bank of integrated data for the development of bespoke personalized treatments for pancreatic cancer patients.

Clinical Trials Analysis

Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math

Amgen walks through its price-setting model for PCSK9 inihibitor Repatha and says new outcomes data just presented at ACC provides more evidence that "prices that exist in the market are indeed value-based."

Health Technology Assessment Reimbursement

Will Physician Demand For Repatha Put Pressure On Payer Restrictions?

FOURIER outcomes data presented at the American College of Cardiology annual meeting fell short of expectations, but could increase physician demand for the PCSK9 inhibitor, making it harder for payers to say no.

Reimbursement Market Access

Zika Vaccines Might Be Approved By 2020

Nothing's even in Phase II yet, but sponsors and US government researchers remain optimistic.

Vaccines Research & Development

AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza

Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in Phase III for ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling without pivotal data in this population.

Cancer Clinical Trials

Antibacterial Development: Industry Cautious About Role Of Animal Models

Payers and prescribers, not just the US FDA, need to understand the basis of approval, John Rex says.

Research & Development Drug Approval Standards
See All
UsernamePublicRestriction

Register